Objective: How to study the neuroprotective and autophagy effects of artesunate on experimental autoimmune encephalomyelitis (EAE) mice?
Method: Do you want to randomly select 48 C57BL/6 mice as an empty group? Model group: Artesunate low-dose group and high-dose group. There are 4 groups, each with 12 animals. Use MOG35-55 peptide to create EAE model. Artesunate (10 mg) was given to the low-dose and high-dose artesunate groups. /(Kg?D), 50mg/(kg?D)) intraperitoneal injection, observe the mice for 10 consecutive days? The brain tissue was stained with Luxor Fast Blue (LFB), demyelination was observed, and the expression of autophagy-related proteins LC3 and LC3-II was detected by Western blot-I?
Result: No mice in the blank group were sick. Model group? Artesunate mice in each dose group showed varying degrees of sagging, unstable gait and hindlimb weakness. Compared with the model group, the incubation period, delayed peak period and neurological function scores of each dose group of artesunate were lower. The effect of the low-dose group in the high-dose group was significant (P0.05)? (2) LFB staining showed that the myelin sheath in the model group was relaxed. How has the disease, low staining and myelin staining improved in each treatment group of Artesnart? (3) Compared with the blank group in the Western blot detection model group, the optical density of LC3-I and LC3-II bands and the ratio of LC3-II/LC3-I in each dose group of artesunate and the comparison model group LC3I to LC3II. The ratio of the optical density value of this band to LC3-II/LC3-I decreased (P\u003c0.01). Is there a significant effect in the low-dose group (P\u003c0.05)?
Conclusion: Artesunate has a neuroprotective effect on EAE mice, which may be the same as reducing brain demyelination and down-regulating LC3-I. Will LC3-II and LC3-II/LC3-I reduce autophagy?